BERTAM, 9 December 2016 – The Advanced Medical and Dental Institute (AMDI) of Universiti Sains Malaysia (USM) today had a reception for the delegates from Aurigene Discovery Technologies Limited India, led by its Chief Executive Officer Chavali S.N.Murthy and accompanied by 5 other officers.

It was the group's turn to visit USM, as the USM Vice-Chancellor Professor Datuk Dr. Asma Ismail and AMDI Director Dr. Norehan Mokhtar had visited the Aurigene facility as part of their education study tour in India last month.

According to Asma, continued efforts should be focused on future research collaborations and the availability of top-class facilities for training.

"Through this cooperation with Aurigene, I hope to build an entrepreneurial mindset for USM communities and also move science forward to the next level," she said when chairing the strategic partnership meeting between USM and Aurigene at AMDI here today.

Asma also stated that lecturers and students will be sent to India for 6 weeks training in collaboration with Aurigene.

Meanwhile the USM Deputy Vice-Chancellor (Research and Innovation), Professor Dato' Dr. Muhamad Jantan in welcoming the delegates, said that this strategic meeting and discussion session was aimed to further develop collaboration initiatives between USM and Aurigene in the future.

"This session could be used to discuss positive and concrete measures in order for both parties to work together in the clinical area and also other areas of interest," he said.

Dr. Norehan gave a brief presentation on AMDI, while the Deputy-Director of AMDI Dr. Nazarah Yusoff presented the research and innovation ecosystem at AMDI, focusing on clinical, research and academic activities utilising a self-sustaining model.

This was followed by a short visit to the Oncology Department and also the animal research facility, led by AMDI Deputy-Director Dr. Muhamad Yusri Musa.

Aurigene is a specialised biotech company, and is committed towards the vision of becoming the most respected and highly-valued biotech company in India.

With its focus on oncology and inflammatory diseases, Aurigene has put its wide expertise in therapeutic areas into practice, gained from the experiences of doing multiple programmes, to deliver both small molecule and peptide drug candidates to its biotech and pharmaceutical partners.

Aurigene has pioneered a unique model on Drug Discovery collaborations with large pharmaceuticals, midsize pharmaceutical companies and biotech firms.

Besides the Engineering Campus academic and administrative staff, also present were the Director of International Collaboration Professor Dr. Lee Keat Teong and Dean of School of Biological Sciences, Professor Dr. Amirul Al-Ashraf Abdullah.

Text: Hafiz Meah Ghouse Meah / Photo: Mohd Fairus Md Isa